Table 5.
Treatment approaches in countries that recommend treating children and/or adolescents for HCV.
| Country | Year | Paediatric treatment recommendations |
|---|---|---|
| Armenia | DAAs for 12–18-year-olds. | |
| Brazil | 2019 | DAAs for 12–18-year-olds. IFN and RBV for 3–12-year-olds regardless of hepatic enzyme abnormalities. |
| Cambodia | 2019 | IFN and RBV for 2–18-year-olds. Treatment not recommended for children under the age of 2. HCV infected children to be monitored for liver disease progression. |
| Chile | 2015 | IFN and RBV for 2–18-year-olds. Treat GT 1 and GT 4 for 48 weeks; and GT 2 and GT 3 for 24 weeks. |
| China | 2019 | DAAs for 12–18-year-olds using: glecaprevir/pibrentasvir for all GTs with or without cirrhosis; sofosbuvir/ledipasvir for GT 1, 4, 5, and 6 and sofosbuvir and ribavirin for GT 2 and 3. |
| Czech Republic | 2019 | DAAs (sofosbuvir/ledipasvir) for 12–18-year-olds or those >35 kg. Defer treatment for those under 12 years of age until DAAs are available. |
| Dominican Republic | 2018 | DAAs for age groups in which DAA-based regimens are available. Treatment not recommended for children under the age of 3. |
| Egypt∗,† | n.a. | DAAs for 12–17-year-olds. |
| Germany | 2018 | DAAs for age groups in which DAA-based regimens are available. Treatment not recommended for children under the age of 3. |
| Greece | 2017 | DAAs for age groups in which DAA-based regimens are available. Treatment not recommended for children under the age of 3. |
| Hungary | 2018 | DAAs (sofosbuvir and ledipasvir) for 12–18-year-olds or those >35 kg IFN and RBV for 3–12-year-olds. |
| Iceland | 2016 | Treatment may be considered for 16–18-year-olds. |
| Kazakhstan | 2019 | DAAs for 12–18-year-olds. IFN and RBV for 3–12-year-olds in exceptional cases. |
| Korea, Republic of | 2017 | IFN and RBV for 3–18-year-olds |
| Kyrgyzstan | 2011 | Treatment for children indicated but regimen not specified. |
| Latvia | 2017 | IFN and RBV for 2–18-year-olds |
| Lebanon | n.a. | IFN and RBV |
| Luxembourg | 2018 | Treatment for children indicated but regimen not specified. |
| Malaysia | 2019 | DAAs for 12–18-year-olds using: sofosbuvir/ledipasvir for GT 1, 4, 5, and 6 and sofosbuvir and ribavirin for GT 2 and 3. |
| Maldives | 2019 | DAAs for 12–18-year-olds using: sofosbuvir/ledipasvir for GT 1, 4, 5, and 6 and sofosbuvir and ribavirin for GT 2 and 3. |
| Mexico | 2016 | IFN and RBV |
| Moldova, Republic of | 2017 | Treatment for children indicated but regimen not specified. |
| Mongolia | 2019 | DAAs for 12–18-year-olds using sofosbuvir/ledipasvir. |
| Nepal | 2019 | DAAs for 12–18-year-olds using sofosbuvir/ledipasvir. |
| Pakistan∗,† | n.a. | IFN and RBV (guidelines) Defer treatment for those under 12 years of age until DAAs are available. |
| Philippines | 2020 | DAAs for 12–18-year-olds using: sofosbuvir/velpastavir; glecaprevir/pibrentasvir; sofosbuvir/daclatasvir; sofosbuvir/daclatasvir. |
| Poland | 2016 | IFN and RBV for 3–18-year-olds |
| Russia∗ | 2016 | Interferon-alpha AND ribavarin |
| Sweden | 2018 | DAAs for 12–18-year-olds using: sofosbuvir/ledipasvir 12 weeks for GT 1 or 4 and sofosbuvir/ribavirin 12–24 weeks for GT 2 or 3 Option to use sofosbuvir/velpatasvir 12 weeks for GT 2 or 3 |
| Ukraine∗,†,‡ | 2016 | IFN and RBV for 3–18-year-olds Treatment not recommended for children under the age of 3. |
| UK | 2013 | IFN and RBV |
| USA | 2018 | DAAs for age groups in which DAA-based regimens are available. Defer treatment for 3–12-year-olds until DAAs are available. |
| Uzbekistan∗ | 2011 | IFN and RBV |